Cambridge University Hospitals NHS Foundation Trust

Their core work

Cambridge University Hospitals NHS Foundation Trust (CUH) operates Addenbrooke's Hospital and the Rosie Hospital in Cambridge, making it one of the UK's largest NHS teaching hospital trusts. In EU-funded research, CUH functions as a clinical partner: it provides patient recruitment capacity, clinical trial infrastructure, and access to well-phenotyped disease cohorts that academic or industry partners alone cannot supply. Their H2020 participation spans a cell therapy clinical trial for osteoarthritis (ADIPOA2) and a large-scale molecular stratification programme for autoimmune and inflammatory diseases (3TR). As a hospital co-located with the University of Cambridge, they translate basic science into clinical settings and supply the real-world patient data that makes precision medicine research actionable.

What they specialise in

How they've shifted over time

In the first half of their H2020 period (2015-2019), CUH's involvement was anchored in a defined interventional clinical trial — testing a cell therapy product in osteoarthritis patients — with no associated computational or genomics keywords. By the second project (2019-2026), the focus had shifted entirely toward complex multi-disease programmes where stratification, predictive modelling, single-cell data, and integrative genomics are central. This mirrors a sector-wide transition: from CUH executing protocol-driven trials toward CUH contributing clinical cohorts and real-world data to computationally intensive precision medicine platforms.

CUH is moving from a conventional clinical trial site role toward a clinical data and cohort provider for large precision medicine consortia — making them an increasingly relevant partner for any programme that needs validated, well-phenotyped patient populations in autoimmunity, inflammation, or allergy.

How they like to work

CUH holds zero coordinator roles across both projects, consistently joining as a participant or third party — a pattern typical of NHS hospitals that bring clinical access rather than research leadership. Their 105 unique consortium partners from just 2 projects signals involvement in very large, multi-site European programmes rather than targeted bilateral collaborations. For prospective partners, this means CUH is an experienced consortium member that knows how to operate within complex governance structures, but it also means they are unlikely to drive a project's scientific agenda.

Across just 2 projects, CUH has worked alongside 105 unique partners spanning 16 countries — a figure almost entirely driven by 3TR, one of the largest autoimmunity RIAs funded under H2020. Their network is pan-European in character, with no evidence of geographic concentration beyond the UK.

What sets them apart

CUH is uniquely positioned at the intersection of a major NHS clinical operation and the University of Cambridge research ecosystem — a combination that is difficult to replicate anywhere in Europe. For consortium builders in precision medicine, cell therapy, or autoimmune disease, CUH offers something academic partners cannot: direct access to NHS patient populations, clinical trial regulatory experience, and the credibility that comes with a nationally recognised hospital brand. Their modest EC funding footprint relative to their network size suggests they contribute more in kind (patient access, data) than they receive in cash — a cost-effective entry point for a consortium needing clinical validation.

Highlights from their portfolio

• 3TR
  One of the most ambitious H2020 precision medicine programmes (2019-2026), spanning autoimmunity, allergy, and inflammatory bowel disease with over 100 consortium partners — CUH's third-party role here signals their standing as a trusted clinical site in pan-European disease research.
• ADIPOA2
  A landmark multicentre clinical trial of adipose-derived mesenchymal stromal cell therapy for osteoarthritis — CUH's participation as a funded site confirms their capacity to handle advanced therapy medicinal product (ATMP) trials under EU regulatory frameworks.